Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H40O5 |
Molecular Weight | 432.5928 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2
InChI
InChIKey=GGXICVAJURFBLW-CEYXHVGTSA-N
InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
Molecular Formula | C26H40O5 |
Molecular Weight | 432.5928 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020597s045s048lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/9698288 | https://www.ncbi.nlm.nih.gov/pubmed/21788077Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/29194198 | https://clinicaltrials.gov/ct2/show/NCT01895972 | https://www.ncbi.nlm.nih.gov/pubmed/28783422 | https://clinicaltrials.gov/ct2/show/NCT01749904
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020597s045s048lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/9698288 | https://www.ncbi.nlm.nih.gov/pubmed/21788077
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/29194198 | https://clinicaltrials.gov/ct2/show/NCT01895972 | https://www.ncbi.nlm.nih.gov/pubmed/28783422 | https://clinicaltrials.gov/ct2/show/NCT01749904
Latanoprost (free acid) is a metabolite of latanoprost which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester prodrug which is converted to the Latanoprost-acid by endogenous esterase enzymes. The free acid is pharmacologically active and is 200 times more potent than latanoprost as an agonist of the human recombinant Prostaglandin F receptor. However, the free Latanoprost-acid is more irritating and less effective than Latanoprost when applied directly to the eyes of human glaucoma patients.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P43088 Gene ID: 5737.0 Gene Symbol: PTGFR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10634944 |
3.6 nM [EC50] | ||
Target ID: CHEMBL1987 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9733584 |
|||
Target ID: CHEMBL1987 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VYZULTA Approved UseVYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension Launch Date1.48668482E12 |
|||
Primary | VYZULTA Approved UseVYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension Launch Date1.48668482E12 |
|||
Primary | VYZULTA Approved UseYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Launch Date1.50949436E12 |
|||
Primary | VYZULTA Approved UseYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Launch Date1.50949436E12 |
|||
Palliative | XALATAN Approved UseXALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch Date8.3393282E11 |
|||
Primary | XALATAN Approved UseXALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch Date8.3393282E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
53 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/ |
1.5 μg single, ocular dose: 1.5 μg route of administration: Ocular experiment type: SINGLE co-administered: |
LATANOPROST ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.15 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/ |
3 μg/kg bw single, intravenous dose: 3 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
LATANOPROST ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
34 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/ |
1.5 μg single, ocular dose: 1.5 μg route of administration: Ocular experiment type: SINGLE co-administered: |
LATANOPROST ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/ |
3 μg/kg bw single, intravenous dose: 3 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
LATANOPROST ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
17 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/ |
1.5 μg single, ocular dose: 1.5 μg route of administration: Ocular experiment type: SINGLE co-administered: |
LATANOPROST ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.005 % 1 times / day multiple, topical Recommended Dose: 0.005 %, 1 times / day Route: topical Route: multiple Dose: 0.005 %, 1 times / day Sources: |
unhealthy, mean age 63.1 years n = 289 Health Status: unhealthy Condition: open-angle glaucoma | ocular hypertension Age Group: mean age 63.1 years Sex: M+F Population Size: 289 Sources: |
Disc. AE: Iritis, Meibomianitis... AEs leading to discontinuation/dose reduction: Iritis (grade 2, 0.3%) Sources: Meibomianitis (grade 1, 0.3%) |
11 ug/kg multiple, topical MTD Dose: 11 ug/kg Route: topical Route: multiple Dose: 11 ug/kg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: |
healthy Health Status: healthy Sources: |
Other AEs: Abdominal pain, Dizziness... Other AEs: Abdominal pain Sources: Dizziness Fatigue Hot flushes Nausea Sweating |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Meibomianitis | grade 1, 0.3% Disc. AE |
0.005 % 1 times / day multiple, topical Recommended Dose: 0.005 %, 1 times / day Route: topical Route: multiple Dose: 0.005 %, 1 times / day Sources: |
unhealthy, mean age 63.1 years n = 289 Health Status: unhealthy Condition: open-angle glaucoma | ocular hypertension Age Group: mean age 63.1 years Sex: M+F Population Size: 289 Sources: |
Iritis | grade 2, 0.3% Disc. AE |
0.005 % 1 times / day multiple, topical Recommended Dose: 0.005 %, 1 times / day Route: topical Route: multiple Dose: 0.005 %, 1 times / day Sources: |
unhealthy, mean age 63.1 years n = 289 Health Status: unhealthy Condition: open-angle glaucoma | ocular hypertension Age Group: mean age 63.1 years Sex: M+F Population Size: 289 Sources: |
Abdominal pain | 10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: |
healthy Health Status: healthy Sources: |
|
Dizziness | 10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: |
healthy Health Status: healthy Sources: |
|
Fatigue | 10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: |
healthy Health Status: healthy Sources: |
|
Hot flushes | 10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: |
healthy Health Status: healthy Sources: |
|
Nausea | 10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: |
healthy Health Status: healthy Sources: |
|
Sweating | 10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: |
healthy Health Status: healthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf#page=342 Page: 342.0 |
unlikely | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf#page=342 Page: 342.0 |
unlikely |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
unlikely | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/20019365/ Page: 6.0 |
weak | |||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. | 1993 May |
|
A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. | 1996 Aug |
|
Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. | 1996 Jan |
|
Mechanism of prostaglandin E2-, F2alpha- and latanoprost acid-induced relaxation of submental veins. | 1997 Dec 11 |
|
The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. | 1997 Feb |
|
Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. | 1997 Sep |
|
Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. | 1998 Apr |
|
Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. | 1998 May |
|
A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy. | 2000 Jul-Sep |
|
[Increased iris pigmentation after use of latanoprost in Japanese brown eyes]. | 2001 May |
|
Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. | 2002 Jan |
|
Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. | 2004 Sep |
|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 Nov |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Sample Use Guides
One drop in the affected eye(s) once daily in the evening.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27749098
Latanoprost above concentrations of 3.125 mg/l can induce dose- and time-dependent morphological abnormality, growth retardation, viability decline, and plasma membrane permeability elevation of human corneal stromal (HCS) cells. Moreover, latanoprost can arrest the cell cycle of these cells at S phase and induce PS externalization, DNA fragmentation, and apoptotic body formation of the cells. Furthermore, latanoprost can induce activation of caspase-3, -8 and -9; disruption of MTP; downregulation of anti-apoptotic Bcl-2; upregulation of pro-apoptotic Bax; and cytoplasmic cytochrome c release
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:08:45 UTC 2023
by
admin
on
Wed Jul 05 23:08:45 UTC 2023
|
Record UNII |
6Z5B6HVF6O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01EE01
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
||
|
NDF-RT |
N0000007706
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
||
|
NCI_THESAURUS |
C29705
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
||
|
WHO-ATC |
S01EE01
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
||
|
NDF-RT |
N0000007706
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
||
|
NDF-RT |
N0000175454
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
||
|
NCI_THESAURUS |
C78568
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
||
|
NDF-RT |
N0000007706
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6Z5B6HVF6O
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
DTXSID1041057
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
100000092301
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
II-6
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
Latanoprost
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
CHEMBL1051
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
6384
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
6980
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
C072042
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
C29151
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
LATANOPROST
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
130209-82-4
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
1551
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
SUB08409MIG
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
6Z5B6HVF6O
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
1357475
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
DB00654
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
43611
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
1961
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
5311221
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | |||
|
M6701
Created by
admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
There is an equilibrium between the acid and the lactone
MAJOR
FECAL; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|